Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making
April 1, 2009
From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.
|
February 1, 2009
Convert future revenue into present value with alternative approaches to access capital.
|
September 1, 2008
By:
Joanna Breitstein
The industry is a-changing. Here are eight seminal events that describe how.
|
February 1, 2008
By:
The Pharm Exec staff
Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007.
|
September 1, 2007
By:
Joanna Breitstein
here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value.
|
July 3, 2007
The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases
|
June 1, 2007
By:
Michael Goodman
While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.
|
May 1, 2007
Back in 2003, Roche resolved a long-standing lawsuit with Igen International by acquiring the company. As part of the deal, Roche acquired a perpetual license to use the Igen technology that gave rise to the lawsuit—electrochemiluminescence (ECL)—in certain applications. Igen's ECL patents, meanwhile, were assigned to a new publicly held spin-off company focusing on biosecurity testing, clinical point-of-care products, and vaccines. In March, Roche announced that it was acquiring the spin-off, Maryland-based BioVeris, for $21.50 per share, or a total of about $600 million.
|
May 1, 2007
By:
Diane West
Direct-to-consumer advertising officially becomes a "tweenager" this August—and, oh my, how it has grown. DTC was officially born in 1997 when FDA gave the green light to companies to advertise their drugs to consumers. In the first year, pharmaceutical marketers bounded onto the scene and spent more than $1 billion. Years passed. Debates ensued. Patients learned more about drugs. And, yes, spending grew. The latest available figures for 2006 show that the industry spent $4.8 billion on DTC advertising, a 13 percent increase over 2005 and the second year of double-digit growth.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
